Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02349360 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability and Host Response to Lactobacillus Johnsonii

A Phase 1 study, sponsored by University of Florida.

Completed
Registry status
Phase 1
Development phase
42
Enrollment target

NCT02349360: Completed Phase 1 study, sponsored by University of Florida.

NCT02349360 is a Phase 1 study that has completed, run by University of Florida. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02349360, a Phase 1 study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 1
Development phase
42 participants
Enrollment target

Study Summary

The purpose of this research study is to determine the effects of the probiotic, Lactobacillus johnsonii N6.2, on safety, gastrointestinal function, wellness, fecal bacteria and blood biomarkers in healthy individuals.

Primary Outcome

The number of participants reporting Adverse Events was reported.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL L. johnsonii N6.2

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2015-08
Est. Completion 2016-12
Phase Phase 1
University of Florida

1,106 total trials

What the finished NCT02349360 record still lists

NCT02349360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02349360 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02349360 about?

NCT02349360 is a clinical study titled "Safety, Tolerability and Host Response to Lactobacillus Johnsonii". The purpose of this research study is to determine the effects of the probiotic, Lactobacillus johnsonii N6.2, on safety, gastrointestinal function, wellness, fecal bacteria and blood biomarkers in healthy individuals.

What is the current status of trial NCT02349360?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2015-08. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02349360?

The interventions under investigation include: Placebo (BIOLOGICAL), L. johnsonii N6.2 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02349360?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02349360's enrollment target sits among peer trials

42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02349360, the US trial registry maintained by the National Library of Medicine. NCT02349360 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.